NIST, NCI, SAIC partner on new method for detecting HER2 breast cancerFebruary 20, 2008Generations of mothers have served up chicken soup to remedy the common cold, but now the therapeutic fowl may find use in diagnosis as well. Researchers at the National Institute of Standards and Technology (NIST), the National Cancer Institute (NCI) and the scientific research firm SAIC recently showed how chicken antibodies may one day improve the detection of an aggressive form of breast cancer. HER2 is one of a family of genes that help regulate the growth and proliferation of human cells. Normal cells have two copies of HER2, but about 20 to 25 percent of breast cancers have multiple copies of the gene, resulting in the overproduction of a HER2-encoded protein (called HER2) that stimulates tumors to be particularly fast growing and difficult to treat in a subset of breast cancer patients. Patients with that form of breast cancer-about 40,000 women in the United States annually-can be treated with a monoclonal antibody called trastuzumab that targets and inhibits the growth of tumor cells with higher-than-normal levels of the HER2 protein. But because the treatment can have adverse side effects, it's important to screen for those patients who would benefit from it by testing them for one or both of the two relevant biomarkers: the amplified HER2 gene or its overexpressed HER2 protein. Unfortunately, the existing tests for these biomarkers can yield a significant number of false positives-as many as 23 percent of patients in one 2006 clinical study-resulting in some women getting a somewhat risky and expensive treatment that can't help them.
In a paper in the International Journal of Cancer,* the NIST-NCI-SAIC research team found that chicken immunoglobulin Y (IgY) antibody created against the HER2 protein could be tagged with quantum dot (tiny, intense and tunable sources of colorful light) to more reliably detect the HER2 biomarker than the existing diagnostic tests using mammalian antibodies tagged with conventional fluorescent dyes. Overall, the improvement in sensitivity to the HER2 biomarker was about 40-50 percent. The increased sensitivity of the HER2 quantum dot-based quantitative bioimaging system stems from the broad genetic differences between avian and human species. The chicken IgY antibody to HER2 reacts strongly with the target protein while ignoring other human proteins that can interfere with current diagnostic tests. Other advantages of the novel NIST-NCI-SAIC system include faster and larger-scale production of the antibodies and a more reliable quantitative measure of HER2 biomarker level, in part because the quantum dot tags will stay bright and detectable while fluorescent dyes fade over time. National Institute of Standards and Technology (NIST) | |||||||||||||||||||||
|
Related Breast Cancer Current Events and Breast Cancer News Articles Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics Novel platform technologies and key advances in genomics are rapidly driving the development of molecular diagnostics, reports Genetic Engineering and Biotechnology News (GEN). Study looks at psychological impact of gene test for breast cancer Personal beliefs about inconclusive DNA testing for hereditary breast cancer are associated with cancer-related worry, and such beliefs are an especially strong predictor of whether women had been able to leave the period of DNA-testing behind. Second lumpectomy for breast cancer reduces survival rates A majority of women with breast cancer today are candidates for lumpectomy, allowing for conservation of most of their breast tissue. MRI spots DCIS in mice A new magnetic resonance imaging procedure can detect very early breast cancer in mice, including ductal carcinoma in situ (DCIS), a precursor to invasive cancer. Some of the tumors detected were less than 300 microns in diameter, the smallest cancers ever detected by MRI. Birth size is a marker of susceptibility to breast cancer later in life Birth size, and in particular birth length, correlates with subsequent risk of breast cancer in adulthood, according to a new study published in PLoS Medicine by researchers at the London School of Hygiene and Tropical Medicine. Social class dictates cancer risk Cervical and lung cancer are more common in poor people while rates of breast cancer and melanoma are higher in the wealthy. Cancer patients who receive neoadjuvant therapy followed by mastectomy may not need radiation Early-stage breast cancer patients who exhibit limited lymph node involvement may not require post-surgery radiation therapy (RT) when they receive neoadjuvant chemotherapy before a mastectomy, according to researchers from The University of Texas M. D. Anderson Cancer Center. New predictive tool can help determine treatment of breast cancer patients A new predictive measurement, called a PEPI score, could bring good news to many women diagnosed with early stage breast cancer - a low PEPI (preoperative endocrine prognostic index) score could show that they have little risk of relapse and can safely avoid chemotherapy after surgery. The dietary supplement genistein can undermine breast cancer treatment Women taking aromatase inhibitors to treat breast cancer or prevent its recurrence should think twice before also taking a soy-based dietary supplement, researchers report. Racial disparities decline for cancer in Missouri Cancer death rates in the United States are highest among African Americans, but a new report shows that in Missouri the disparity in cancer incidence and death between African Americans and whites is declining. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||